WO2022269027 - ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS
National phase entry:
Publication Number
WO/2022/269027
Publication Date
29.12.2022
International Application No.
PCT/EP2022/067318
International Filing Date
24.06.2022
Title **
[English]
ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS
[French]
ANTAGONISTES DE CXCR4 À BASE D'ISOQUINOLÉINE ET DE PYRIDINE
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
KU Leuven R&D Waaistraat 6 - box 5105
3000 Leuven, BE
Inventors
DEHAEN, Wim
Groenstraat 173
3001 Leuven, BE
DE JONGHE, Steven
Olmenstraat 23
3080 Tervuren, BE
SCHOLS, Dominique
Keierveld 9
3020 Herent, BE
VAN LOY, Tom
Zoerleberg 24
2260 Zoerle-Parwijs, BE
Priority Data
21181444.7
24.06.2021
EP
21204648.6
26.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1122 | |
| EPO | Filing, Examination | 4649 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 2710 |
Total: 9678 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to isoquinoline and pyridine based CXCR4 antagonists and their use in the treatment and prevention of viral infections such as HIV.[French]
L'invention concerne des antagonistes CXCR4 à base d'isoquinoléine et de pyridine et leur utilisation dans le traitement et la prévention d'infections virales telles que le VIH.